GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (STU:UXI) » Definitions » Short Percentage of Float

Cyclacel Pharmaceuticals (STU:UXI) Short Percentage of Float


View and export this data going back to 2010. Start your Free Trial

What is Cyclacel Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Cyclacel Pharmaceuticals's Short Percentage of Float

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclacel Pharmaceuticals's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's Short Percentage of Float falls into.


Cyclacel Pharmaceuticals (STU:UXI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (STU:UXI) » Definitions » Short Percentage of Float
Comparable Companies
REVB BTAX TSOI CPMV APVO AXIM EIGRQ FNCH SEEL ACUT OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
CYCCP.PFD:USA CYCC:USA
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Website
https://www.cyclacel.com
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Cyclacel Pharmaceuticals (STU:UXI) Headlines

No Headlines